Dianthus Therapeutics (DNTH) Net Cash Flow (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Net Cash Flow of $42.7 million for Q3 2025, up 115.23% year-over-year from $19.8 million in Q3 2024, and up 1267.61% quarter-over-quarter from $3.1 million in Q2 2025.
Dianthus Therapeutics (DNTH) Net Cash Flow (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at $42.7 million for Q3 2025.
- In Q3 2025, Net Cash Flow rose 115.23% year-over-year to $42.7 million; the TTM figure through Dec 2025 stood at $33.1 million (up 130.29% YoY), while the FY2024 annual figure was -$109.4 million, down 193.5% from the prior year.
- Net Cash Flow for Q3 2025 stood at $42.7 million, up from $3.1 million in the prior quarter.
- The five-year high for Net Cash Flow was $197.4 million in Q1 2024, with the low at -$280.3 million in Q3 2024.
- The 5-year median for Net Cash Flow is -$8.9 million (2021), against an average of $6.4 million.
- Peak annual rise in Net Cash Flow reached 4136.37% in 2022, while the deepest fall reached 575.67% in 2022.
- Dianthus Therapeutics' Net Cash Flow stood at -$25.9 million in 2021, then grew by 16.89% to -$21.5 million in 2022, then decreased by 15.99% to -$25.0 million in 2023, then jumped by 56.41% to -$10.9 million in 2024, then jumped by 492.38% to $42.7 million in 2025.
- Business Quant data shows DNTH's Net Cash Flow at $42.7 million in Q3 2025, $3.1 million in Q2 2025, and -$12.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 42.68 Mn |
| Sep 30, 2025 | 42.68 Mn |
| Jun 30, 2025 | 3.12 Mn |
| Jun 30, 2025 | 3.12 Mn |
| Mar 31, 2025 | -12.68 Mn |
| Mar 31, 2025 | -12.68 Mn |
| Dec 31, 2024 | -10.88 Mn |
| Dec 31, 2024 | -10.88 Mn |
| Sep 30, 2024 | -280.34 Mn |
| Sep 30, 2024 | -280.34 Mn |
| Jun 30, 2024 | -15.56 Mn |
| Jun 30, 2024 | -15.56 Mn |
| Mar 31, 2024 | 197.40 Mn |
| Mar 31, 2024 | 197.40 Mn |
| Dec 31, 2023 | -24.96 Mn |
| Dec 31, 2023 | -24.96 Mn |
| Sep 30, 2023 | 116.94 Mn |
| Sep 30, 2023 | 116.94 Mn |
| Jun 30, 2023 | 17.13 Mn |
| Jun 30, 2023 | 17.13 Mn |